Effect of estrogen on outcome in two randomized phase III studies of paclitaxel poliglumex (PPX) in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
O'Byrne, K.
Singer, J. W.
Oldham, F. B.
Ross, H.
机构：
[1] St James Hosp, Dublin 8, Ireland
[2] Cell Therapeut, Seattle, WA USA
[3] Earle A Chiles Res Inst, Portland, OR USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70650-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
645
引用
收藏
页码：194 / 195
页数：2
相关论文
共 50 条
  • [21] A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Blumenschein, GR
    Khuri, F
    Gatzemeier, U
    Miller, WH
    von Pawel, J
    Rigas, JR
    Herbst, RS
    Dziewanowska, Z
    Negro-Vilar, A
    Mabry, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1094S - 1094S
  • [22] Tolerability and activity of weekly paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)
    Fabi, A
    De Marco, S
    Barduagni, M
    Gamucci, T
    Cortesi, E
    De Marinis, F
    Ferraresi, V
    Saltarelli, R
    Gabriele, A
    Accettura, C
    Cognetti, F
    ANNALS OF ONCOLOGY, 2000, 11 : 4 - 4
  • [23] A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Gatzemeier, U
    Blumenschein, G
    Jotte, R
    von Pawel, J
    Miller, W
    Khuri, F
    Rigas, J
    Mabry, M
    Dziewanowska, Z
    Negro-Vilar, A
    LUNG CANCER, 2005, 49 : S31 - S31
  • [24] Concurrent chemoradiotherapy with paclitaxel and carboplatin for locoregionally advanced non-small cell lung cancer (NSCLC)
    Kaplanova, J.
    Tomiskova, M.
    Babickova, L.
    Kadlec, B.
    Slampa, P.
    Skrickova, J.
    LUNG CANCER, 2006, 52 : S34 - S34
  • [25] Randomized phase III study of Gemcitabine/cisplatin versus mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer (NSCLC)
    Scagliotti, G
    Crino, L
    Conte, PF
    Rinaldi, M
    De Marinis, F
    Gridelli, C
    ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
  • [26] A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC).
    Johnson, EA
    Marks, RS
    Mandrekar, S
    Hillman, S
    Mailliard, J
    Dentchev, T
    Reuter, N
    Jett, J
    Perez, EA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 634S - 634S
  • [27] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Charlotte D. Jacobs
    Quincy Chu
    Eric K. Rowinsky
    Arturo Lopez-Anaya
    Chris H. Takimoto
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 825 - 834
  • [28] Weekly paclitaxel in advanced non-small cell lung cancer
    Chang, AYC
    Rubins, J
    Asbury, R
    Boros, L
    Hui, LF
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 10 - 13
  • [29] Phase II study of celecoxib and weekly paclitaxel in the treatment of pretreated advanced non-small cell lung cancer (NSCLC).
    Stani, SC
    Carillio, G
    Meo, S
    Morabito, A
    Bonginelli, P
    Comella, G
    Mansueto, G
    Avallone, A
    Gion, M
    Gasparini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 700S - 700S
  • [30] Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX).
    Bonomi, P.
    Langer, C.
    O'Brien, M.
    O'Byrne, K.
    Bandstra, B.
    Paz-Ares, L.
    Ross, H.
    Sandler, A.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 374S - 374S
12345